SCHEMBL1801328

SCHEMBL1801328

[CH2]COC(=O)CCC(=O)OC[CH2]

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.42
ADRA1A P35348 1/20 0.42
TSHR P16473 3/20 0.40
MAPT P10636 1/20 0.40
BLM P54132 1/20 0.40
ALDH1A1 P00352 1/20 0.36
DGKA P23743 1/20 0.33
CYP1A2 P05177 1/20 0.33
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30
HTR2C P28335 1/20 0.30
PAM P19021 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835054 0.89 LMNA (0.47) ADRA2AADRA1ATSHRMAPTBLM
SCHEMBL16765644 0.89 ADRA2A (0.36) ADRA2AADRA1ATSHRMAPTBLM
SCHEMBL9387033 0.87 TSHR (0.65) ADRA2AADRA1ATSHRMAPTBLM
SCHEMBL4294657 0.85
SCHEMBL49969 0.85
SCHEMBL7787557 0.83
SCHEMBL8924003 0.83
SCHEMBL14889189 0.83
SCHEMBL10470529 0.83
SCHEMBL7696786 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
EP-2011811-B1 ACTIVE RAY CURABLE COMPOSITION, ACTIVE RAY CURABLE INKJET INK, IMAGE FORMING METHOD USING THE ACTIVE RAY CURABLE INKJET INK, AND INKJET RECORDING APPARATUS KONICA MINOLTA MED & GRAPHIC (JP) 2015-03-18 EP disclosed
US-8642675-B2 Actinic ray curable composition, actinic ray curable ink-jet ink, image forming method and ink-jet recording apparatus utilizing said actinic ray curable ink-jet ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2014-02-04 US disclosed
EP-2347904-B1 Ink set and ink-jet recording method utilizing uv-curable ink KONICA MINOLTA MED & GRAPHIC (JP) 2013-04-03 EP disclosed
EP-2347904-A2 Inkset, ink-jet recording method and ink-jet recording device utilizing uv-curable ink Konica Minolta Medical & Graphic, Inc. (JP) 2011-07-27 EP disclosed
US-7950795-B2 Image forming method and ink-jet recording device utilizing photo-curable ink, and inkset, ink-jet recording method and ink-jet recording device utilizing photo-curable ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2011-05-31 US disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2009-02-12 US disclosed
US-20080180501-A1 Actinic Ray Curable Composition, Actinic Ray Curable Ink, Image Forming Method Utilizing the Same, Ink-Jet Recording Apparatus and Epoxy Compound KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-07-31 US disclosed
US-7390840-B2 Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-06-24 US disclosed
US-7360883-B2 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-04-22 US disclosed
US-20080055379-A1 Image Forming Method and Ink-Jet Recording Device Utilizing Photo-Curable Ink, and Inkset, Ink-Jet Recording Method and Ink-Jet Recording Device Utilizing Photo-Curable Ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2008-03-06 US disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
US-20070254977-A1 Actinic ray curable composition, actinic ray curable ink-jet ink, image forming method and ink-jet recording apparatus utilizing said actinic ray curable ink-jet ink KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2007-11-01 US disclosed
EP-1837357-A1 ACTINIC RAY CURABLE COMPOSITION, ACTINIC RAY CURABLE INK, METHOD OF IMAGE FORMING THEREWITH, INKJET RECORDING APPARATUS AND EPOXY COMPOUND Konica Minolta Medical & Graphic, Inc. (JP) 2007-09-26 EP disclosed
EP-1826005-A1 IMAGE FORMING METHOD AND INKJET RECORDING DEVICE USING PHOTO-CURING INK, AND INK SET, INKJET RECORDING METHOD AND INKJET RECORDING DEVICE USING PHOTO-CURING INK Konica Minolta Medical & Graphic, Inc. (JP) 2007-08-29 EP disclosed
US-20050215657-A1 Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same KONICA MINOLTA MEDICAL & GRAPHIC, INC. 2005-09-29 US disclosed
US-20050190252-A1 Active ray curable ink, image forming method and ink-jet recording apparatus KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080180501-A1 Actinic Ray Curable Composition, Actinic Ray Curable Ink, Image Forming Method Utilizing the Same, Ink-Jet Recording Apparatus and Epoxy Compound ROCK1, MACF1, ACTN1 ADRA2A 2778/4885ADRA1A 2579/4885TSHR 4600/4885
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 ADRA2A 3439/4885ADRA1A 3926/4885TSHR 1319/4885
US-20090041945-A1 ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS RIF1, NAP1L4, NAP1L1 ADRA2A 3412/4885ADRA1A 2935/4885TSHR 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.